Skip to main content

Table 2 Characteristics and outcomes of people admitted for PD without COVID-19

From: COVID-19 outcomes in hospitalized Parkinson’s disease patients in two pandemic waves in 2020: a nationwide cross-sectional study from Germany

 

March–May (1st wave)

October–December (2nd wave)

2nd versus 1st (2020)

2020 versus 2019 (1st)

2020 versus 2019 (2nd)

2020

2019

2020

2019

RR

95% CI

RR

95% CI

RR

95% CI

LL

UL

 

LL

UL

 

LL

UL

N

6618

 

11,820

 

7802

 

10,129

 

n.a

n.a

n.a

n.a

n.a

n.a

n.a

n.a

n.a

Demographics

Age (M, SD, relative difference)

73.8

8.4

73.9

8.4

73.3

8.2

73.9

8.4

− 0.006*

n.a

n.a

−0.002†

n.a

n.a

− 0.007‡

n.a

n.a

Female gender

2497

37.7%

4727

40.0%

3104

39.8%

3971

39.2%

1.054

1.012

1.099

0.943

0.908

0.980

1.015

0.978

1.053

Care dependency (OPS 9-984.6/7/8/9/a)

3918

59.2%

6527

55.2%

4470

57.3%

5537

54.7%

0.968

0.941

0.995

1.072

1.045

1.100

1.048

1.021

1.076

PD characteristics

HY < 3 (G20.0)

785

11.9%

1434

12.1%

933

12.0%

1356

13.4%

1.008

0.922

1.102

0.978

0.901

1.061

0.893

0.826

0.966

HY 3–4 (G20.1)

4381

66.2%

7923

67.0%

5320

68.2%

6782

67.0%

1.030

1.007

1.054

0.988

0.967

1.009

1.018

0.998

1.039

HY 5 (G20.2)

838

12.7%

1381

11.7%

824

10.6%

1071

10.6%

0.834

0.762

0.913

1.084

1.000

1.174

0.999

0.917

1.088

HY n.s. (G20.9)

614

9.3%

1082

9.2%

725

9.3%

920

9.1%

1.002

0.904

1.110

1.014

0.922

1.114

1.023

0.932

1.123

Motor fluctuations (G20.-1)

4159

62.8%

7176

60.7%

4671

59.9%

6254

61.7%

0.953

0.928

0.978

1.035

1.011

1.060

0.970

0.947

0.993

Comorbidities

Diabetes mellitus, type 2 (E11)

1072

16.2%

1953

16.5%

1168

15.0%

1608

15.9%

0.924

0.856

0.997

0.980

0.916

1.049

0.943

0.880

1.011

Obesity (E66)

175

2.6%

383

3.2%

214

2.7%

310

3.1%

1.037

0.852

1.263

0.816

0.684

0.973

0.896

0.755

1.064

Hypertension (I10)

3290

49.7%

5762

48.7%

3623

46.4%

4899

48.4%

0.934

0.903

0.966

1.020

0.989

1.051

0.960

0.931

0.991

Chronic ischaemic heart disease (I25)

822

12.4%

1403

11.9%

812

10.4%

1174

11.6%

0.838

0.765

0.918

1.046

0.965

1.134

0.898

0.825

0.977

Cerebrovascular disease (I69)

200

3.0%

342

2.9%

212

2.7%

261

2.6%

0.899

0.743

1.088

1.044

0.880

1.240

1.055

0.882

1.261

COPD (J44)

179

2.7%

338

2.9%

171

2.2%

275

2.7%

0.810

0.659

0.997

0.946

0.791

1.131

0.807

0.669

0.975

Chronic kidney disease (N18)

698

10.5%

1215

10.3%

832

10.7%

1040

10.3%

1.011

0.919

1.112

1.026

0.940

1.121

1.039

0.953

1.132

Outcomes

In-hospital mortality (07)

117

1.8%

135

1.1%

82

1.1%

130

1.3%

0.594

0.449

0.787

1.548

1.211

1.979

0.819

0.622

1.078

ICU treatment (OPS 8-980/8-98f)

236

3.6%

302

2.6%

215

2.8%

227

2.2%

0.773

0.644

0.927

1.396

1.180

1.650

1.230

1.023

1.478

  1. HY Hoehn and Yahr stage, n.s. not specified, n.a. not applicable, significant results (p < 0.05) are marked in bold
  2. *p = 0.0003, t(14,418) = 3.61; †p = 0.438, t(18,436) = 0.78; ‡p < 0.0001, t(17,929) = 4.79
Back to article page

Neurological Research and Practice

ISSN: 2524-3489

Contact us